Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD
Merck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung disease, while also succeeding in a separate mid-stage study for ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.